CD31-ITAM Bispecific Platform

About Tridek-One

Tridek-One is a preclinical-stage biotech developing a novel class of immune-modulating therapies targeting the CD31 (PECAM-1) inhibitory checkpoint. The company's core technology is a bispecific antibody platform that combines anti-CD31 agonism with cell-specific targeting via ITAM receptors, aiming to deliver localized immunosuppression with a reduced risk of systemic side effects. Financed by leading European venture capital firms, the company has raised approximately €11 million in equity and secured €1.9 million in non-dilutive Deeptech financing. Tridek-One is led by a seasoned management team with deep expertise in biologics development and immunology.

Therapeutic Areas

Other Autoimmune and Inflammatory Diseases Drugs